© 2024 © 2020 Genprex Inc. All Rights Reserved.
Presentation to Highlight Company’s Gene Therapies for Cancer and Diabetes
Expects to Complete Enrollment of Phase 2a Expansion Study by the end of 2024
Genprex today announced that on February 2, 2024, the Company will implement a 1-for-40 reverse split of its issued and outstanding common stock, par value $0.001 per share.
Acclaim-1 Phase 2a and Acclaim-3 Phase 1 clinical studies opening for enrollment in January 2024
Poised for FDA guidance regarding diabetes gene therapy program in 2024
Presentation to be held on Tuesday, November 7, 2023 from 4:45 – 5:00 p.m. UTC
Webinar to be held on Friday, October 27, 2023 from 12:30 pm – 1:45 pm Eastern Time
Acclaim-1 Phase 1 study had no Dose Limiting Toxicity, and results establish Phase 2 Recommended Dose as well as provide data showing efficacy of REQORSA® in combination with Tagrisso®
Presentation to Highlight Company’s Gene Therapies for Cancer and Diabetes
Strengthens management team with seasoned regulatory expert to support pipeline of gene therapies for the treatment of cancer and diabetes, including two clinical trials in Non-Small Cell Lung Cancer and one in Small Cell Lung Cancer
ODD is in addition to Three FDA Fast Track Designations